Our findings share several similarities with the results of a short‐term CUA in the UK setting that was based on clinical outcomes from the DEVOTE basal‐bolus subgroup.26 Pollock et al. reported that degludec was dominant relative to glargine U100 over a 2‐year time horizon in patients with T2D at high cardiovascular risk who were using a basal‐bolus insulin regimen. Here, INS is linked to type 2 diabetes mellitus.